ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use

AstraZeneca

ULTOMIRIS is a complement inhibitor indicated for:

• the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)
• the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)

Limitations of Use:

• ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

• the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Store ULTOMIRIS vials refrigerated at 2°C – 8°C (36°F – 46°F) in the original carton to protect from light.

Do not freeze. Do not shake.